Related references
Note: Only part of the references are listed.American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Gary H. Lyman et al.
BLOOD ADVANCES (2021)
Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis
Ella Grilz et al.
EUROPEAN HEART JOURNAL (2021)
Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis
Ella Grilz et al.
EUROPEAN HEART JOURNAL (2021)
2019 ESC Guidelines for the dignosis and management of acute pulmonary embolism development Toed in colaboration with the European Respiratory Society (ERS)
Stavros Konstantinides et al.
EUROPEAN HEART JOURNAL (2020)
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
Nigel S. Key et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial
Robert D. McBane et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembolica Registry
Iva Golemi et al.
JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS (2020)
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis
Frits Mulder et al.
BLOOD (2020)
Pharmacological cancer treatment and venous thromboembolism risk
Andres J. Munoz Martin et al.
EUROPEAN HEART JOURNAL SUPPLEMENTS (2020)
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism
Waldemar E. Wysokinski et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
1774PPatient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer
A T Cohen et al.
ANNALS OF ONCOLOGY (2019)
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
Dominique Farge et al.
LANCET ONCOLOGY (2019)
Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience
Gerald A. Soff et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2019)
Arterial Ischemic Events Are a Major Complication in Cancer Patients with Venous Thromboembolism
Benjamin Brenner et al.
AMERICAN JOURNAL OF MEDICINE (2018)
Statistical primer: sample size and power calculations-why, when and how?
Graeme L. Hickey et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2018)
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH
A. A. Khorana et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study
Alexander T. Cohen et al.
THROMBOSIS JOURNAL (2018)
Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice
S. J. van der Wall et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
The management of acute venous thromboembolism in clinical practice Results from the European PREFER in VTE Registry
Alexander T. Cohen et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Epidemiology of first and recurrent venous thromboembolism in patients with active cancer A population-based cohort study
Alexander T. Cohen et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study
Luis Jara-Palomares et al.
THROMBOSIS RESEARCH (2017)
Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis
Alok A. Khorana et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2017)
Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
Clive Kearon et al.
CHEST (2016)
Guidance for the treatment of deep vein thrombosis and pulmonary embolism
Michael B. Streiff et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2016)
Overview of the New Oral Anticoagulants Opportunities and Challenges
Calvin H. Yeh et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer A Randomized Clinical Trial
Agnes Y. Y. Lee et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12months: the DALTECAN Study
C. W. Francis et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Management of thrombosis in cancer: primary prevention and secondary prophylaxis
AYY Lee
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
AYY Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
